Pages

Thursday, November 4, 2010

台灣國家生技研究園區: 只有中研院才能帶動產業群聚效益???????

國家生技研究園區 3月內有譜  

11/4 12:05】〔中央社〕中央研究院長翁啟惠今天表示,國家生技研究園區開發案1025日已經送環評,至於環評是否能通過,最快3個月內就知道,若通過,明年初馬上開始動工,「沒有通過就不會做」。中研院今天到立法院教育及文化委員會進行100年度施政計畫及收支預算案口頭報告,國民黨籍立委蔣乃辛、黃志雄、鄭金玲和賴士葆等多名立委關心國家生技研究園區開發案,翁啟惠答詢時作上述表示。翁啟惠表示,盡最大誠意持續與環保團體溝通,這也是台灣必須要加強的地方,改過的計畫,興建的量體減少,並且濕地、滯洪量增加,國家生技研究園區開發案已經在1025日送環保署,進入環評程序。翁啟惠認為,環評是否會通過,最快3個月內會知道,如果環評通過,將會馬上動工,預計仍是在民國105年完工。翁啟惠說,如果環評沒有通過,就不會做,也不會考慮到其他地方,因為這邊最少投資效益最高;他解釋,國家生技研究園區要在中研院旁邊,才能發揮群聚效應,方便互動並充分利用中研院的設備、硬體、學術研究成果等。鄭金玲再度建議中研院搬到桃園青埔去,當地民眾都歡迎。翁啟惠說,全台灣目前有9個縣市歡迎中研院,他衷心感謝;如果要到其他縣市,他考慮到南部設分院,與南部學術單位互動,強化文化與農業方面的研究。

 

生技園區 翁啟惠:環評過才做 3個月有眉目

2010/11/04 12:27 報導 】國家生技園區開發案十月下旬送環評,中研院院院長翁啟惠表示,過程中將持續與環團溝通,預估最快三個月內會有眉目,只要環評過關年初馬上動工,原訂民國105年營運的時程沒有改變,並強調環評不過就不會做。(陳奕華報導)中研院院長翁啟惠4號到立法院教育及文化委員會進行業務報告,202兵工廠開發案引發的生態與生技之爭,成為討論焦點,翁啟惠強調,會盡最大誠意與環團溝通,此外,回應環團的聲音,修正過後的開發計畫,不僅興建的量體減少,濕地、滯洪量增加,已經在十月25號送環評,對於環評結果,翁啟惠有信心,預估最快三個月內有眉目,一旦通過,就可以立即動工,要是環評沒有通過,就不會做,不過也有多位立委問到,202兵工廠爭議仍在,是否考量生技園區搬遷其他地方,翁啟惠認為,這個地點投資較小效益最高,目前不會考慮到其他地方。「(立委:所以院長的意思是,如果可能會到南部去?)院長:南部設分院,不是這個園區,(立委:南部設分院?)這個園區沒有辦法做,就不能做、就不要做。」現階段有其他九個縣市歡迎中研院前往,翁啟惠表示感謝,也說若要到其他縣市,會考慮到南部設分院,與當地學術單位交流,加強文化與農業研究。

 

翁啟惠:生技園區不在南港 就不蓋

開發案送環評 明年一月揭曉〔記者湯佳玲/台北報導〕國家生技研究園區開發案已送交環評,中研院院長翁啟惠昨天在立法院表示,明年一月就能得知環評結果,只要通過就馬上動工,「如果沒通過,就不能做了,不考慮移往其他縣市。」立法院教育及文化委員會審查中研院一百年度預算時,立委黃志雄質詢指出,韓國已有四種藥物通過美國食品藥物管理局審核,台灣至今仍只有保健食品,如果只開發四公頃會不會影響到未來台灣生技發展?建議「改址」可以是方案之一。

翁啟惠則指出,台灣生技產業排名世界第十三位,且三分之一都來自中研院,但是如何產業化、創造社會利益,需要創造一種商業模式。

翁不考慮改址 李遠哲聲援; 儘管目前已有九個縣市表態歡迎中研院,翁啟惠說,南部可以設立中研院的分院,強化文化與農業方面的研究,「但那會是分院,不是生技園區,如果南港生技園區做不成,就不能做了」。翁啟惠指出,國家生技研究園區要在中研院旁邊,才能發揮群聚效益,方便互動並充分利用中研院的設備、硬體、學術研究成果等。前中研院院長李遠哲昨天表示,當初是帶生態保育專家進入評估,南港生技園區大部分留給自然,開發的只有現在就已經開發的四.六公頃火工區。主張可以遷往別處的人,可能不了解研究人員需要時常進出實驗室以及研究上的「群聚效益」。

生技新藥發展條例修正初審不過: 擴大獎勵也需考慮利益迴避條款

Taiwan: 生技新藥條例修正 初審沒過

2010-11-05 工商時報;生技新藥發展條例第3條修正草案立院初審意外被封殺!藍綠立委質疑,業界施壓政府放寬該條例租稅優惠適用對象,因此立法院經濟委員會昨(4)日決定暫時不審查,將擇期召開公聽會後再說。立法院經委會昨日審查生技新藥條例第3條修正草案,經濟部建議修正適用租稅優惠的高風險醫療器材定義,由現行條文「植入或置入人體內屬的第三類等級之醫療器材」,修改為「第三類等級的醫療器材」。工業局表示,生技新藥條例自民國96年公布之後,僅有科研、和康、喜樂、怡忠與雙美,總計5家醫療器材廠商取得生技新藥條例的租稅優惠,顯見醫療器材適用門檻過高,建議修改放寬醫療器材標準,把「植入或置入人體內」的要件拿掉。一旦拿掉植入或置入人體內的要件,工業局舉例,體外試驗劑、醫療電子或隱形眼鏡等,均可以納入租稅獎勵研發項目。然而,民進黨立委翁金珠質疑,3年前才三讀通過的法條,此時提出要修正放寬適用範圍,而且只修正高風險醫療器材項目,固然會讓人疑慮,經濟部是否遭到施壓,建議先召開公聽會,廣聽外界意見之後再審查法案。民進黨立委黃淑英則說,有鑑於今年6月中研院生醫所所長陳垣崇疑似涉入貪污圖利之嫌,認為經濟部應該在生技新藥條例訂定利益迴避條款。民進黨立委黃偉哲表示,生技新藥條例可能會與產創條例發生競合關係,廠商可以拿某些項目申請生技新藥租稅獎勵,其餘則去申請產創條例的研發抵減,如今,政府又放寬醫療器材適用範圍,不太妥當。施顏祥回應,生技新藥適用的租稅獎勵優於產創條例。國民黨立委丁守中認為,經濟部提出建議修正的理由,無法說服大眾。

Sanofi strategically deployment in China feminine drug market by BMP Sunstone (美華太陽石) acquisition

Sanofi Makes a Big Push in China

October closes with almost $1 billion in IPOs, $3 billion in M&A activity, and potentially $3 billion in partnering deals. MARIE DAGHLIAN. The Burrill Report Sanofi-Aventis reinforced its presence in China with the acquisition of BMP Sunstone for $521 million in cash, representing a 30 percent premium above the closing price of Sunstone's shares before its board of directors unanimously approved the transaction. The merger follows the recent formation of Hangzhou Sanofi Minsheng Consumer Healthcare joint venture and will make the pharmaceutical powerhouse a leading consumer healthcare company in China. "The acquisition of BMP Sunstone will not only leverage our consumer healthcare business in China, but will also bring us unique access to new expanding distribution channels which are expected to account for a third of the pharmaceutical market in China in the coming years," says Sanofi CEO Chris Viehbacher. BMP Sunstone is a specialty pharmaceutical that manufactures pediatric and women's health products sold in pharmacies throughout China and had sales of approximately $147 million in 2009, 60 percent of which were in the consumer health segment. The company also markets a portfolio of products under exclusive multi-year licenses in China, primarily focused on women's health and pediatrics, and provides pharmaceutical distribution services through subsidiaries in Beijing and Shanghai. Sanofi has been moving aggressively into the consumer healthcare market as a way to diversify and grow the company as several of its biggest drugs go off patent. The company claims to be the fifth largest consumer healthcare company in the world, since its acquisition of U.S. consumer products company Chattem in 2009. China's market for these products is second only to the United States and has grown at 11 percent per year since 2005, a trend that is expected to continue as its middle class grows and becomes more urban. Sanofi already has a major presence in China with 5,000 people in more than 200 cities and three manufacturing facilities, and a large research and development center in Shanghai. Completion of the transaction is subject to Chinese regulatory approval and to the approval of BMP Sunstone stockholders, 23 percent of which have committed to vote in favor of the merger. Sanofi was not the only pharmaceutical company crossing borders to do a deal. Israeli generic powerhouse Teva Pharmaceuticals went to Germany to acquire Théramex, Merck KGaA's women's health business for $367 million. Théramex's products are sold in 50 countries worldwide, including countries in which Teva will acquire distribution rights. Théramex has built an especially solid reputation in France and Italy as a company dedicated to women's health and gynecology. In addition to Teva's upfront cash payment, Merck will be eligible to receive certain performance-based milestone payments. The transaction is expected to close towards the end of this year or in early 2011. Jordanian pharmaceutical Hikma is expanding its global injectables portfolio and its U.S. market presence through the acquisition of Baxter's multi-source injectables business for $112 million in cash. The deal will position Hikma as the second largest injectables supplier in the United States with a combined market share of more than 15 percent. Biotech companies also reaped the rewards of a busy week of dealmaking. MacroGenics enriched its coffers with two drug discovery deals with big pharmaceutical companies—Boehringer Ingelheim and Pfizer will use its antibody platform directed at multiple targets. Rockville, Maryland-based MacroGenics expects to receive at least $60 million from Boehringer and could get up to $210 million more for the successful development of each of up to ten therapeutics developed by the collaboration. The collaboration with Pfizer is focused on cancer. Financial terms were not disclosed. Seattle's Immune Design granted MedImmune exclusive worldwide rights to use its novel early stage adjuvant in vaccines for select infectious diseases. In return, Immune Design will get an upfront licensing fee and potential development, regulatory and commercial milestones of up to $212 million, in addition to royalty payments on sales of marketed products. Amicus Therapeutics licensed Amigal, its late stage Fabry Disease drug, to GlaxoSmithKline for $30 million upfront, up to $170 million in milestone payments, as well as significant royalties on global sales. GSK is also taking a 20 percent stake in the New Jersey biotech for another $31 million. As part of their agreement, the companies also intend to advance clinical studies exploring the co-administration of Amigal with enzyme replacement therapy to treat Fabry Disease. Finally, Pacific Biosciences went public, pricing 12.5 million shares at $16 each to raise $200 million. The company is developing DNA sequencing machines that promise to sequence the genome faster, cheaper, and more accurately.

 

Deals for the Week Ending October 29, 2010

 

 

 

 

 

Global Venture Financings

 

 

 

 

 

 

Company

Location

Amount Raised (USD M)

Principal Focus

aTyr Pharma

San Diego, CA

23.0

Therapeutics-protein drugs

ContraFect

New York, NY

14.2

Therapeutics-infectious

Solx

Sudbury, MA

3.7

Medical devices

CardioNexus

Houston, TX

N/A

Diagnostics

Cappella

Galway, Ireland

14.6

Medical devices

Mind-NRG

Geneva, Switzerland

14.0

Therapeutics-CNS

EntreChem

Oviedo, Spain

2.0

Therapeutics-cancer

Biopta

Glasgow, Scotland

0.4

Tools/Technology

Curefab

Munich, Germany

N/A

Diagnostics

 

 

 

 

Total Raised US

 

40.9

 

Total Raised Non-US

 

31.0

 

 

 

 

 

Grants and Contracts

 

 

 

 

 

 

 

Company

Funding/Contracting Agency

Amount Raised (USD M)

Principal Focus

Grants

 

 

 

Rockland Immunochemicals

NIH Phase I SBIR

N/A

Generic antibodies

Galapagos (Belgium)

Flemish agency for Innovation

5.1

Cystic fibrosis

Contracts

 

 

 

SAIC

US DoD 3-year task order

23.0

Biometrics

 

 

 

 

Total Grants and Contracts

28.1

 

 

 

 

 

PUBLIC FINANCINGS

 

 

 

 

 

 

 

Company

Ticker

Amount
Raised (USD M)

Financing Type

Sihuan Pharmaceutical

HK:0460

741

IPO

Pacific Biosciences

PACB

200

IPO

Stentys

Euronext:STNT

31.9

IPO

PURE Bioscience

PURE

2.4

PIPE

DARA BioSciences

DARA

1.4

PIPE-RDO

InVivo Therapeutics

OTC:NVIV

10.5

PIPE

AVEO Pharmaceuticals

AVEO

61.0

PIPE

PharmAthene

PIP

15.0

PIPE-RDO

Sirona Biochem (Canada)

TSX-V:SBM

1.0

PIPE

Ariad Pharmaceuticals

ARIA

59.2

Follow on

Oncolytics Biotech (Canada)

ONCY

24.0

Follow on

Sigma-Aldrich

SIAL

300.0

Debt

Omeros

OMER

25.0

Right to percentage of net proceeds

Ore Pharmaceuticals

OTC:ORXE

5.3

Debt and equity

Amicus Therapeutics

FOLD

31.0

GSK takes 20 percent equity stake

 

 

 

 

TOTAL PUBLIC FINANCINGS-US

710.8

 

NON-US

797.9

 

 

 

 

 

M&A

 

 

 

Acquirer

Target

Deal Value
(USD M)

Focus

Stryker

Boston Scientific's neurovascular business

1,500.0

Medical devices

Sanofi-Aventis (France)

BMP Sunstone (China)

520.6

Specialty pharma

Teva Pharmaceuticals (Israel)

Theramex (Merck KGaA-Germany)

367.0

Women's health

Green Plains Renewable Energy

Global Ethanol

169.0

Renewable fuels

Hikma Pharmaceuticals (Jordan)

Baxter's Injectables business

112.0

Generic injectables

Kadmon Pharmaceuticals

Three Rivers Pharmaceuticals

100.0

Specialty pharma

Endologix

Nellix

54.0

Medical devices

Colorplast (Denmark)

Mpathy Medical

35.0

Female pelvic health

Leadtec Systems Australia

Mimotopes (Commonwealth Biotechnologies)

1.1

Tools/Technology

 

 

 

 

Alliances

 

 

 

Company/Licensee

Company/Licenser

Deal Value
(USD M)

Focus

Boehringer Ingelheim (Germany)

MacroGenics

2,160.0

Antibody Therapeutics Alliance

MedImmune (AstraZeneca-UK)

Immune Design

212.0

Vaccine Adjuvant License and Collaboration

GlaxoSmithKline (UK)

Amicus Therapeutics

200.0

Fabry Disease License

Pfizer and four other pharmas

Ablexis

55.0

Drug Discovery Platform License

Biovail (Valeant)

Acadia Pharmaceuticals

8.8

Conclusion of Parkinson's Collaboration

NeuroVive (Sweden)

to-BBB (the Netherlands)

N/A

Neurology Partnership

Millennium (Takeda-Japan)

Therasis

N/A

Drug Discovery Collaboration

Celtic Therapeutics

Resolvyx Pharmaceuticals

N/A

Opthalmic drug Option agreement

Pfizer

MacroGenics

N/A

Cancer License and Collaboration

Abbott Laboratories

Myriad Genetics

N/A

Companion Diagnostic Cooperative Agreement

Jingxin Pharmaceutical (China_

Evotec (Germany)

N/A

Insomnia Drug License

Seattle Genetics

Compugen (Israel)

N/A

Oncology Collaboration and License Option